Developer docs
API playgroundTry for free, no card

Search company profiles

Avinnogen

Full company profile

uuid00w4lvk

Namestring
Avinnogen
Legal namestring
Avinnogen Co., Ltd.
Websiteurl
avinnogen.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Avinnogen Co., Ltd. is a privately held South Korean biotechnology company founded in 2022 as a faculty spin-out from Seoul National University, headquartered at the SNU campus in Gwanak-gu, Seoul, with a second R&D facility opened in Bundang in October 2025. The company develops and applies a proprietary Primordial Germ Cell (PGC)-mediated gene editing platform for avian species, producing three lines of business: custom gene-edited chickens used as models and antibody-producing lines, an egg bioreactor platform that uses gene-edited chicken eggs as living bioreactors to manufacture therapeutic proteins and antibodies with human-like glycosylation, and high-value functional eggs (nutrient-fortified and low-cholesterol variants). Two internal pipeline candidates — AVN-001 for autoimmune disease therapy and AVN-002 for recombinant blood factor production — are in preclinical development using the same platform.

The company monetizes primarily through professional-services engagements for custom gene-edited chicken production (deliverables and IP transfer exclusively to the client), with stated but undisclosed licensing economics for egg bioreactor-derived protein production, and longer-term consumer upside through enhanced nutritional egg products. Customers are described by vertical — pharmaceutical and biotechnology research institutions for antibody and disease-model work, pharmaceutical companies seeking cost-effective protein production, and food and agricultural buyers for functional eggs — but no named customer logos or contracted revenue were disclosed, and pricing is not publicly listed; all commercial engagement runs through inquiry-based contact channels. Distribution is direct, enterprise, and global in stated scope, with primary operating geography in South Korea.

Avinnogen is operating in early-stage, grant-and-services mode rather than commercial-revenue mode. The company has secured multiple Korean government non-dilutive programs (TIPS in August 2024, Young Researcher Support in June 2023, IP-R&D Strategy Support in 2024 and 2025, Regional Industry Promotion in 2024), earned Venture Company and Startup Business certifications, received an undisclosed investment round from Mira Partners Individual Investment Association and JOIN Co., Ltd. in August 2025, and in July 2025 hired its first disclosed CTO (Hongjo Lee) and CSO/Executive Vice President (Youngmin Kim). The combination of an academic-originated proprietary biological platform, preclinical-stage therapeutic pipeline, services-based near-term revenue model, and reliance on Korean public funding programs characterizes a typical Korean preclinical spin-out building toward an inflection point rather than a commercial-stage business.

Short descriptiontext

Avinnogen is a South Korean preclinical biotechnology company that uses proprietary avian primordial germ cell gene editing to produce custom gene-edited chickens, an egg-based bioreactor for therapeutic proteins, and high-value functional eggs for pharmaceutical and food-industry customers.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
avian gene editing, therapeutic protein production, egg bioreactor platform, biopharmaceutical manufacturing, recombinant antibody production
Industry3 codes
PRIMARYAFAGAIAG
Biotechnology & Gene-Edited Trait Development
Agriculture & Food Production/Crop Farming/Seed Production & Plant Breeding (Seed Multiplication, Hybrid Seed, Certified Seed)
SECONDARYAFAEADAD
Hatcheries & Chick Production (Day-Old Chicks, Pullets)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Poultry Hatcheries112340
  • Other Poultry Production11239
SIC code1 code
  • Agricultural Prod-Livestock & Animal Specialties200
Product category
Avian Biotechnology and Biopharmaceutical Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Custom Gene-Edited Chicken Production Services
TypeProfessional Services
Description

Custom gene-edited chicken production services for various research and commercial purposes including antibody production, disease-resistant breed development, embryology research, human disease modeling, and drug development. Deliverables and IP from start to finish belong exclusively to the client.

avinnogen.com
2Egg Bioreactor Protein Production
TypeOne Time License
Description

Therapeutic protein and antibody production using gene-edited eggs as bioreactors. Products include AVN-001 for autoimmune disease therapy and AVN-002 for recombinant blood factor production.

avinnogen.com
3High-Value Egg Products
TypeHardware Sales
Description

Functional enhanced egg products with improved nutritional profiles including nutrient-fortified eggs and low-cholesterol eggs that overcome limitations of conventional eggs.

avinnogen.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Avinnogen produces gene-edited birds and useful substances using its proprietary avian Primordial Germ Cell (PGC)-mediated gene editing platform. Its commercial offerings include custom gene-edited chicken production services for antibody production and disease modeling, an egg bioreactor platform for manufacturing therapeutic proteins and antibodies with human-like glycosylation, and high-value functional egg products such as nutrient-fortified and low-cholesterol eggs. The company also develops pipeline therapeutic candidates AVN-001 and AVN-002.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Industry-leading gene-edited success rates
+1 more record
Product overview1 text field

Avinnogen is a biotechnology company offering a portfolio of avian gene-editing products and services centered on its proprietary PGC (Primordial Germ Cell) technology platform. The core offerings include Gene-Edited Chicken production services for antibody production and disease research, an Egg Bioreactor platform for therapeutic protein manufacturing, and High-Value Eggs as functional food products. The company also maintains a pipeline of therapeutic candidates including AVN-001 for autoimmune disease and AVN-002 for recombinant blood factor production, developed through gene-edited chicken systems.

Product and service3 records
1Gene-Edited Chicken Production Service
CategoryAvian gene-editing services
Description

Custom gene-edited chicken production services using Avinnogen's proprietary PGC-mediated gene editing technology. Delivered to pharmaceutical companies, biotech firms, and research institutions for antibody production, recombinant protein platforms, disease-resistant breed development, embryology and gene function research, human disease modeling, and drug development. All deliverables and IP from start to finish belong exclusively to the client.

2Egg Bioreactor Platform
CategoryBioprocess and therapeutic protein manufacturing
Description

Next-generation biomanufacturing platform that uses gene-edited chicken eggs as living production facilities to mass-produce high-quality therapeutic proteins and antibodies with human-like glycosylation and minimized immune response, supplied to pharmaceutical companies for therapeutic protein production.

3High-Value Functional Eggs
CategoryFunctional food products
Description

Functional enhanced egg products developed through gene editing technology, including nutrient-fortified eggs and low-cholesterol eggs, designed to overcome the nutritional limitations of conventional eggs for food and agricultural industry customers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Gangwon Technopark
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-07-01
Description

Selected for Gangwon Technopark Business Support Program providing regional industry promotion and business support services.

avinnogen.com
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-05-01
Description

Selected for IP-R&D Strategy Support Project to develop intellectual property strategy and support R&D activities.

3Korea Industrial Technology Association (KOITA)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-01
Description

Established an affiliated research institute registered with the Korea Industrial Technology Association (KOITA), establishing formal research institute status.

avinnogen.com
4Seoul National University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

Received faculty startup approval from Seoul National University, establishing the company's origins as a university spin-off with research foundation.

avinnogen.com
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major poultry breeding company owned by Tyson Foods; competes in the same broiler breeding value chain that Avinnogen's disease-resistant breed development targets.

2Genus plc
TypeBroad incumbent
Description

Global animal genetics company with significant poultry and swine lines; a broad incumbent in the same end-market (animal production genetics) and the most likely strategic acquirer or licensing partner for Avinnogen's platform.

TypeBroad incumbent
Description

Multispecies animal breeding company with substantial poultry genetics operations; a broad incumbent in the gene-edited poultry space where Avinnogen competes.

TypeBroad incumbent
Description

World's leading poultry breeding company producing broiler and layer genetic lines; comparable to Avinnogen's gene-edited chicken production services in target customer and use case.

TypeDirect peer
Description

Animal gene editing company focused on livestock genetics and biomedical applications, including disease resistance traits — overlapping with Avinnogen's gene-edited bird and disease-resistant breed work.

TypeRegional player
Description

World's largest contract biologics manufacturer based in South Korea; the dominant Korean and global CMO that Avinnogen would compete with or supply into for therapeutic protein production.

TypeRegional player
Description

Korean biopharmaceutical manufacturer producing biosimilars and biologics at large scale; a regional incumbent defining the Korean biomanufacturing competitive landscape Avinnogen's egg bioreactor must enter.

TypeEmerging player
Description

Biotech using advanced gene and cell engineering for therapeutic and industrial bioproduction; an emerging platform competitor with similar gene-based bio-production technology to Avinnogen's PGC platform.

TypeDirect peer
Description

University of Edinburgh spin-out commercializing transgenic avian technologies for biopharma, including egg-based protein production — directly comparable to Avinnogen's PGC-mediated platform and egg bioreactor strategy.

10Crystal Biosciences (Ligand Pharmaceuticals)
TypeDirect peer
Description

Develops monoclonal antibodies using transgenic chicken egg platforms (OmniAb). Most direct global competitor to Avinnogen's egg bioreactor therapeutic protein approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avinnogen

Avian Biotechnology and Biopharmaceutical Manufacturingavinnogen.com

Avinnogen is a South Korean preclinical biotechnology company that uses proprietary avian primordial germ cell gene editing to produce custom gene-edited chickens, an egg-based bioreactor for therapeutic proteins, and high-value functional eggs for pharmaceutical and food-industry customers.

What Avinnogen does

Avinnogen Co., Ltd. is a privately held South Korean biotechnology company founded in 2022 as a faculty spin-out from Seoul National University, headquartered at the SNU campus in Gwanak-gu, Seoul, with a second R&D facility opened in Bundang in October 2025. The company develops and applies a proprietary Primordial Germ Cell (PGC)-mediated gene editing platform for avian species, producing three lines of business: custom gene-edited chickens used as models and antibody-producing lines, an egg bioreactor platform that uses gene-edited chicken eggs as living bioreactors to manufacture therapeutic proteins and antibodies with human-like glycosylation, and high-value functional eggs (nutrient-fortified and low-cholesterol variants). Two internal pipeline candidates — AVN-001 for autoimmune disease therapy and AVN-002 for recombinant blood factor production — are in preclinical development using the same platform.

The company monetizes primarily through professional-services engagements for custom gene-edited chicken production (deliverables and IP transfer exclusively to the client), with stated but undisclosed licensing economics for egg bioreactor-derived protein production, and longer-term consumer upside through enhanced nutritional egg products. Customers are described by vertical — pharmaceutical and biotechnology research institutions for antibody and disease-model work, pharmaceutical companies seeking cost-effective protein production, and food and agricultural buyers for functional eggs — but no named customer logos or contracted revenue were disclosed, and pricing is not publicly listed; all commercial engagement runs through inquiry-based contact channels. Distribution is direct, enterprise, and global in stated scope, with primary operating geography in South Korea.

Avinnogen is operating in early-stage, grant-and-services mode rather than commercial-revenue mode. The company has secured multiple Korean government non-dilutive programs (TIPS in August 2024, Young Researcher Support in June 2023, IP-R&D Strategy Support in 2024 and 2025, Regional Industry Promotion in 2024), earned Venture Company and Startup Business certifications, received an undisclosed investment round from Mira Partners Individual Investment Association and JOIN Co., Ltd. in August 2025, and in July 2025 hired its first disclosed CTO (Hongjo Lee) and CSO/Executive Vice President (Youngmin Kim). The combination of an academic-originated proprietary biological platform, preclinical-stage therapeutic pipeline, services-based near-term revenue model, and reliance on Korean public funding programs characterizes a typical Korean preclinical spin-out building toward an inflection point rather than a commercial-stage business.

Avinnogen firmographics

Firmographics
Name
Avinnogen
Legal name
Avinnogen Co., Ltd.
Website
https://avinnogen.com
Company type
Private
Founded year
2022
Operating status
Operating
Short description
Avinnogen is a South Korean preclinical biotechnology company that uses proprietary avian primordial germ cell gene editing to produce custom gene-edited chickens, an egg-based bioreactor for therapeutic proteins, and high-value functional eggs for pharmaceutical and food-industry customers.
Ownership category
akta.pro rank

Avinnogen industry classification

Industry
Product category
Avian Biotechnology and Biopharmaceutical Manufacturing
NAICS
Poultry Hatcheries (112340), Other Poultry Production (11239)
SIC
Agricultural Prod-Livestock & Animal Specialties (200)
akta.pro industry
PRIMARYAFAGAIAG
Biotechnology & Gene-Edited Trait Development
Agriculture & Food Production/Crop Farming/Seed Production & Plant Breeding (Seed Multiplication, Hybrid Seed, Certified Seed)
SECONDARYAFAEADAD
Hatcheries & Chick Production (Day-Old Chicks, Pullets)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Avian gene editing
  • Therapeutic protein production
  • Egg bioreactor platform
  • Biopharmaceutical manufacturing
  • Recombinant antibody production

Where Avinnogen is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Avinnogen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Custom Gene-Edited Chicken Production Services: Custom gene-edited chicken production services for various research and commercial purposes including antibody production, disease-resistant breed development, embryology research, human disease modeling, and drug development. Deliverables and IP from start to finish belong exclusively to the client.
  2. Egg Bioreactor Protein Production: Therapeutic protein and antibody production using gene-edited eggs as bioreactors. Products include AVN-001 for autoimmune disease therapy and AVN-002 for recombinant blood factor production.
  3. High-Value Egg Products: Functional enhanced egg products with improved nutritional profiles including nutrient-fortified eggs and low-cholesterol eggs that overcome limitations of conventional eggs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Avinnogen product offering

Product offering

Core offering

Avinnogen produces gene-edited birds and useful substances using its proprietary avian Primordial Germ Cell (PGC)-mediated gene editing platform. Its commercial offerings include custom gene-edited chicken production services for antibody production and disease modeling, an egg bioreactor platform for manufacturing therapeutic proteins and antibodies with human-like glycosylation, and high-value functional egg products such as nutrient-fortified and low-cholesterol eggs. The company also develops pipeline therapeutic candidates AVN-001 and AVN-002.

Product overview

Avinnogen is a biotechnology company offering a portfolio of avian gene-editing products and services centered on its proprietary PGC (Primordial Germ Cell) technology platform. The core offerings include Gene-Edited Chicken production services for antibody production and disease research, an Egg Bioreactor platform for therapeutic protein manufacturing, and High-Value Eggs as functional food products. The company also maintains a pipeline of therapeutic candidates including AVN-001 for autoimmune disease and AVN-002 for recombinant blood factor production, developed through gene-edited chicken systems.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gene-Edited Chicken Production Service Custom gene-edited chicken production services using Avinnogen's proprietary PGC-mediated gene editing technology. Delivered to pharmaceutical companies, biotech firms, and research institutions for antibody production, recombinant protein platforms, disease-resistant breed development, embryology and gene function research, human disease modeling, and drug development. All deliverables and IP from start to finish belong exclusively to the client.
  • Egg Bioreactor Platform Next-generation biomanufacturing platform that uses gene-edited chicken eggs as living production facilities to mass-produce high-quality therapeutic proteins and antibodies with human-like glycosylation and minimized immune response, supplied to pharmaceutical companies for therapeutic protein production.
  • High-Value Functional Eggs Functional enhanced egg products developed through gene editing technology, including nutrient-fortified eggs and low-cholesterol eggs, designed to overcome the nutritional limitations of conventional eggs for food and agricultural industry customers.

Quantifiable outcome

  • Industry-leading gene-edited success rates
  • +1 more outcomes

Companies that use Avinnogen

Customer profile

Segments3 records

Ideal customer profiles2 records

Avinnogen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Avinnogen partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Gangwon TechnoparkminorImplementation/ SI/ Consulting Partner · 1 July 2024Selected for Gangwon Technopark Business Support Program providing regional industry promotion and business support services.
  • Korea Intellectual Property Strategy AgencyminorImplementation/ SI/ Consulting Partner · 1 May 2024Selected for IP-R&D Strategy Support Project to develop intellectual property strategy and support R&D activities.
  • Korea Industrial Technology Association (KOITA)minorStrategic or Co-development Partner · 1 September 2022Established an affiliated research institute registered with the Korea Industrial Technology Association (KOITA), establishing formal research institute status.
  • Seoul National UniversitycoreStrategic or Co-development Partner · 1 March 2022Received faculty startup approval from Seoul National University, establishing the company's origins as a university spin-off with research foundation.

Scale indicators4 records

Recent moves12 records

Expansion highlights5 records

Avinnogen competitors and assessment

Company assessment

Broad incumbents

  • Cobb-Vantress: Major poultry breeding company owned by Tyson Foods; competes in the same broiler breeding value chain that Avinnogen's disease-resistant breed development targets.
  • Genus plc: Global animal genetics company with significant poultry and swine lines; a broad incumbent in the same end-market (animal production genetics) and the most likely strategic acquirer or licensing partner for Avinnogen's platform.
  • Hendrix Genetics: Multispecies animal breeding company with substantial poultry genetics operations; a broad incumbent in the gene-edited poultry space where Avinnogen competes.
  • Aviagen: World's leading poultry breeding company producing broiler and layer genetic lines; comparable to Avinnogen's gene-edited chicken production services in target customer and use case.

Direct peers

  • Recombinetics: Animal gene editing company focused on livestock genetics and biomedical applications, including disease resistance traits — overlapping with Avinnogen's gene-edited bird and disease-resistant breed work.
  • Roslin Technologies: University of Edinburgh spin-out commercializing transgenic avian technologies for biopharma, including egg-based protein production — directly comparable to Avinnogen's PGC-mediated platform and egg bioreactor strategy.
  • Crystal Biosciences (Ligand Pharmaceuticals): Develops monoclonal antibodies using transgenic chicken egg platforms (OmniAb). Most direct global competitor to Avinnogen's egg bioreactor therapeutic protein approach.

Regional players

  • Samsung Biologics: World's largest contract biologics manufacturer based in South Korea; the dominant Korean and global CMO that Avinnogen would compete with or supply into for therapeutic protein production.
  • Celltrion: Korean biopharmaceutical manufacturer producing biosimilars and biologics at large scale; a regional incumbent defining the Korean biomanufacturing competitive landscape Avinnogen's egg bioreactor must enter.

Emerging players

  • Precigen: Biotech using advanced gene and cell engineering for therapeutic and industrial bioproduction; an emerging platform competitor with similar gene-based bio-production technology to Avinnogen's PGC platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Avinnogen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avinnogen leadership team

Management profile

Number of profiles

Profiles2 records

Avinnogen funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avinnogen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avinnogen

What does Avinnogen do?

Avinnogen produces gene-edited birds and useful substances using its proprietary avian Primordial Germ Cell (PGC)-mediated gene editing platform. Its commercial offerings include custom gene-edited chicken production services for antibody production and disease modeling, an egg bioreactor platform for manufacturing therapeutic proteins and antibodies with human-like glycosylation, and high-value functional egg products such as nutrient-fortified and low-cholesterol eggs. The company also develops pipeline therapeutic candidates AVN-001 and AVN-002.

Is Avinnogen a public or private company?

Avinnogen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Avinnogen founded?

Avinnogen was founded in 2022.

Where is Avinnogen based?

Avinnogen is headquartered in Seoul, South Korea, in the Asia region.

How does Avinnogen make money?

Three revenue lines are on record. Custom Gene-Edited Chicken Production Services are the primary driver. The others are egg Bioreactor Protein Production and high-Value Egg Products.

Who are Avinnogen's main competitors?

Broad incumbents on record are Cobb-Vantress, Genus plc, Hendrix Genetics and Aviagen. Direct peers are Recombinetics, Roslin Technologies and Crystal Biosciences (Ligand Pharmaceuticals). Regional players are Samsung Biologics and Celltrion. Precigen is listed as an emerging player.

Does Avinnogen have an API?

No public API is recorded for Avinnogen.

What industry is Avinnogen in?

Avinnogen's product category is Avian Biotechnology and Biopharmaceutical Manufacturing. Its primary akta.pro industry code is AFAGAIAG, Biotechnology & Gene-Edited Trait Development, with a secondary code of AFAEADAD, Hatcheries & Chick Production (Day-Old Chicks, Pullets). Its NAICS code is 112340 and its SIC code is 200.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales